|
|
|
|
Mesenchymal stem cells and their immunological properties
Lisianyĭ MI
Institute of Neurosurgery named after acad.A.P.Romodanov of National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz59.03.126
![](/images/cite.png)
Abstract
Mesenchymal stem cells (MSC) are found in a variety of tissues, including bone marrow, skin and adipose tissue and can be expanded easily in vitro. MSC are thought to have tissue regenerative properties, in the first place via their multilineage differentiation capacity. In addition, MSC have potent immunomodulatory capacity. They inhibit the proliferation of T cells and inhibit dendritic cell maturation. These properties make MSC promising for a diversity of clinical applications; for example, for the prevention and treatment of autoimmune diseases and bone marrow rejection. Different studies have attributed the immunosuppressive effect of MSC to different immunosuppressive factors. These include indoleamine 2,3-dioxygenase (IDO), HLA-G, nitric oxide, interleukines. The long-term ability of allogeneic MSCs to preserve function in the infarcted heart is limited by a biphasic immune response whereby they transition from an immunoprivileged to an immunogenic state after differentiation, which is associated with an alteration in major histocompatibility complex--immune antigen profile. These findings provide critical information about the immunosuppression of MSCs and for better application of MSCs in treating immune disorders.
Keywords:
Mesenchymal stem cells;Immunosuppression;Cytokine; HLA-antigens
References
- Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses . Blood.200. 105. P.1815-1822.
- Al-Refu K., Goodfield M. Hair follicle stem cells inthe pathogenesis of the scarring process in cutaneouslupus erythematosus . Autoimmun. Rev. 2009. 8.P.474-477.
CrossRef
PubMed
- Ankrum J., Karp J.M. Mesenchymal stem cell therapy: twosteps forward, one step back . Trends Mol Med. 2010.-16. P.203-209.
- Atoui R., Shum-Tim D., Chiu R.C. Myocardial regenerativetherapy: immunologic basis for the potential"universal donor cells". Ann Thorac. Surg. 2008. 86. P.327-334.
CrossRef
PubMed
- Augello A., Tasso R., Negrini S.M., Cancedda R., PennesiG. Cell therapy using allogeneic bone marrowmesenchymal stem cells prevents tissue damage incollagen-induced arthritis. Arthritis Rheum. 2007. 56. P.1175-1186.
CrossRef
PubMed
- Cai L., Johnstone B.H., Cook T.G., Tan J., Fishbein M.C.,Chen P.S., March K.L. IFATS collection: Human adiposetissue-derived stem cells induce angiogenesis and nervesprouting following myocardial infarction, in conjunctionwith potent preservation of cardiac function . Stem Cells.-2009. 27. P.230-237.
CrossRef
PubMed PubMedCentral
- Carosella E.D., Moreau P., Le Maoult J. HLA-G molecules:Frommaternal-fetal tolerance to tissue acceptance. Adv. Immunol. 2003. 81. P.199-252.
CrossRef
- Choi E.W., Shin I.S., Lee H.W., Park S.Y., Park J.H., NamM.H., Kim J.S., Woo S.K., Yoon E.J., Kang S.K., RaJ.C., Youn H.Y., Hong S.H. Transplantation of CTLA4Iggene-transduced adipose tissue-derived mesenchymalstem cells reduces inflammatory immune response andimproves Th1/Th2 balance in experimental autoimmunethyroiditis . J. Gene Med. 2011 13. P.3-16.
CrossRef
PubMed
- Choi Y.H., Kurtz A., Stamm C. Mesenchymal stem cellsfor cardiac cell therapy . Hum Gene Ther. 2011. 22.P.3-17.
CrossRef
PubMed
- Colonna M., Navarro F., Bellon T. A common inhibitoryreceptor for major histocompatibility complex class Imolecules on human lymphoidand myelomonocyticcells. J. Exp. Med. 1997. 6. P.1809-1818.
CrossRef
- Corcione A., Benvenuto F., Ferretti E., Giunti D., CappielloV., Cazzanti F., Risso M., Gualandi F., MancardiG.L., Pistoia V., Uccelli A. Human mesenchymal stemcells modulate B-cell functions . Blood. 2006. 107.P.367-372.
CrossRef
PubMed
- Di Nicola M., Carlo-Stella C., Magni M. Human bonemarrow stromal cells suppress T-lymphocyte proliferationinduced by cellular or nonspecific mitogenic stimuli. Ibid. 2002. 99. P. 3838-3843.
- Djouad F., Bouffi C., Ghannam S., Noil D., Jorgensen C.Mesenchymal stem cells: innovative therapeutic toolsfor rheumatic diseases . Nat. Rev. Rheumatol. 2009.5. P.392-399.
- Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P,Bony C, Apparailly F, Cantos C, Jorgensen C, NoelD. Mesenchymal stem cells inhibit the differentiationof dendritic cells through an interleukin-6-dependentmechanism . Stem Cells. 2007. 25. P.2025-2032.
CrossRef
PubMed
- Djouad F., Plence P., Bony C. Immunosuppressive effectof mesenchymal stem cells favors tumor growth in allogeneicanimals . Blood. 2003. 102. P.3837-3844.
CrossRef
PubMed
- Dominici M., Le Blanc K., Mueller I., Slaper-CortenbachI., Marini F., Krause D., Deans R., Keating A., ProckopD., Horwitz E. Minimal criteria for defining multipotentmesenchymal stromal cells. The International Societyfor Cellular Therapy position statement . Cytotherapy.2006. 8. P.315-317.
CrossRef
PubMed
- Edwards T.M., Rickard N.S. New perspectives on themechanisms through which nitric oxide may affectlearning and memory processes . Neurosci. Biobehav.Rev. 2007. 31. P. 413-425.
CrossRef
PubMed
- Garcia-Gomez I., Elvira G., Zapata A.G., Lamana M.L.,Ramorez M., Castro J.G., Arranz M.G., Vicente A.,Bueren J., Garcia-Olmo D. Mesenchymal stem cells:biological properties and clinical applications . Exp.Opin. Biol. Ther. 2010. 10. P.1453-1468.
CrossRef
PubMed
- Grohmann U., Orabona C., Fallarino F. CTLA-4-Igregulates tryptophan catabolism in vivo. Nat. Immunol.-2002. 3. P. 1097-1101.
CrossRef
PubMed
- Hare J.M., Traverse J.H., Henry T.D., Dib N., StrumpfR.K., Schulman S.P. A randomized, double-blind,placebo-controlled, dose-escalation study of intravenousadult human mesenchymal stem cells (prochymal) afteracute myocardial infarction . J. Amer. Coll Cardiol. 2009. 54. P.2277-2286.
CrossRef
PubMed PubMedCentral
- Heiss C., Keymel S., Niesler U. Ziemann J., Kelm M., KalkaC. Impaired progenitor cell activity in age-related endothelialdysfunction . Ibid. 2005. 45. P.1441-1448.
- Hulkower K., Brosnan C.F., Aquino D.A. Expression ofCSF-1, c-fms, and MCP-1 in the central nervous systemof rats with experimental allergic encephalomyelitis . J.Immunol. 1993. 150. P. 2525-2533.
PubMed
- Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D.,Mao N. Human mesenchymal stem cells inhibit differentiationand function of monocyte-derived dendritic cells. Blood. 2005. 105. P.4120-4126.
CrossRef
PubMed
- Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E.,Keene C.D., Ortiz-Gonzalez X.R., Reyes M., Lenvik T.,Lund T., Blackstad M., Du J., Aldrich S., Lisberg A., LowW.C., Largaespada D.A., Verfaillie C.M. Pluripotency ofmesenchymal stem cells derived from adult marrow. Nature. 2002. 418. P.41-49.
CrossRef
PubMed
- Krampera M., Glennie S., Dyson J., Scott D., Laylor R.,Simpson E., Dazzi F. Bone marrow mesenchymal stemcells inhibit the response of naive and memory antigenspecificT cells to their cognate peptide . Blood. 2003.101. P.3722-3729.
- Le Blanc K., Ringden O. Immunomodulation by mesenchymalstem cells and clinical experience . J. Intern.Med. 2007. 262. P.509-525
CrossRef
PubMed
- Lee O.K., Kuo T.K., Chen W.M., Lee K.D., Hsieh S.L.,Chen T.H. Isolation of multipotent mesenchymal stemcells from umbilical cord blood . Blood. 2004. 103.P.1669-1675.
CrossRef
PubMed
- Lila N., Rouas-Freiss N., Dausset J. Soluble HLA-Gprotein secretedby allo-specific CD4_ T cells suppressesthe allo-proliferative response:A CD4_ T cell regulatorymechanism . Proc. Natl. Acad. Sci. USA. 2001. 98.P.12150-12155.
CrossRef
PubMed PubMedCentral
- Liu H., Liu L., Fletcher B.S. Sleeping Beauty-based genetherapy with indoleamine 2,3-dioxygenase inhibits lungallograft fibrosis . FASEB J. 2006. 20. P.2384-2386.
CrossRef
PubMed
- Majumdar M.K., Keane-Moore M., Buyaner D. Characterizationfunctionality of cell surface molecules onhuman mesenchymal stemcells . J. Biomed. Sci. 2003. 10. P.228-241.
CrossRef
- McMaster M.T., Librach C.L., Zhou Y. Human placentalHLA-Gexpression is restricted to differentiated cytotrophoblasts. J. Immunol. 1995. 154. P.3771-3778.
PubMed
- Meirelles Lda S., Fontes A.M., Covas D.T., Caplan A.I.Mechanisms involved in the therapeutic properties ofmesenchymal stem cells . Cytokine Growth Factor Rev.2009. 20. P.419-427.
CrossRef
PubMed
- Meisel R., Zibert A., Laryea M. Human bone marrow stromalcells inhibit allogeneic T-cell responses by indoleamine2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004. 103. P. 4619-4621.
CrossRef
PubMed
- Mellor A.L., Munn D.H. IDO expression by dendriticcells: Tolerance and tryptophan catabolism . Nat. Rev.Immunol. 2004. 4. P. 762-774.
CrossRef
PubMed
- Muller A.J., Prendergast G.C. Indoleamine 2,3-dioxygenasein immune suppression and cancer. Curr CancerDrug Targets. 2007. 7. P. 31-40.
CrossRef
PubMed
- Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol. Med. 2004. 10. P. 15-18.
CrossRef
PubMed
- Nasef A., Chapel A., Mazurier C. Identification of IL-10and TGF-beta transcripts involved in the inhibition ofT-lymphocyte proliferation during cell contact with humanmesenchymal stem cells . Gene Exp. 2007. 13.P.217-226.
CrossRef
PubMed
- Nauta A.J., Fibbe W.E. Immunomodulatory propertiesof mesenchymal stromal cells . Blood. 2007. 110.P.3499-3506.
CrossRef
PubMed
- Oh J.Y., Kim M.K., Shin M.S., Lee H.J., Ko J.H., WeeW.R., Lee J.H. The anti-inflammatory and antiangiogenicrole of mesenchymal stem cells in corneal wound healingfollowing chemical injury . Stem Cells. 2008. 26.P.1047-1055
CrossRef
PubMed
- Papadaki H.A., Kritikos H.D., Gemetzi C., Koutala H.,Marsh J.C., Boumpas D.T., Eliopoulos G.D. Bone marrowcell reserve and function and stromal cellfunction are defective in rheumatoid arthritis: evidencefor a tumor necrosis factor alphamediated effect. Blood.2002. 99. P.1610-1619.
CrossRef
PubMed
- Papadaki H.A., Tsagournisakis M., Mastorodemos V., PontikoglouC., Damianaki A., Pyrovolaki K., StamatopoulosK., Fassas A., Plaitakis A., Eliopoulos G.D. Normal bonehematopoietic stem cell reserves and normalstromal cell function support the use of autologous stemcell transplantation in patients with multiple sclerosis. Bone Marrow Transplant. 2005. 36. P.1053-1063.
CrossRef
PubMed
- Parekkadan B., Milwid J.M. Mesenchymal stem cells as therapeutics . Annu Rev Biomed. Eng. 2010. 12. P.87-117.
CrossRef
PubMed PubMedCentral
- Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells . Science. 1999. 284. P.143-147.
CrossRef
PubMed
- Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics . Circulat. Res. 2004. 36. P.95-99.
CrossRef
- Ra J., Kang S., Shin S. Stem cell treatment for patients with autoimmune disease by systemic infusion of cultureexpanded autologous adipose tissue derived mesenchymal stem cells . J. Transl. Med. 2011. 9. P.181-198.
PubMed PubMedCentral
- Ra J.C., Shin I.S., Kim S.H., Kang S.K., Kang B.C., Lee H.Y., Kim Y.J., Jo J.Y., Yoon E.J., Choi H.J., Kwon E. Safety of intravenous infusion of human adipose tissuederived mesenchymal stem cells in animals and humans . Stem Cells Dev. 2011. 20. P.1295-1296.
CrossRef
PubMed
- Rasmusson I., Ringd N.O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms . Exp. Cell Res. 2005. 305. P.33-41.
CrossRef
PubMed
- Ren G., Zhang L., Zhao X. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide . Cell Stem. Cell. 2008. 2. P. 141-150.
CrossRef
PubMed
- Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., Zhao R.C., Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide . Stem Cells. 2008. 2. P.141-150.
- Ren G., Su F., Zhang L. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression . Stem Cells. 2009. 27. P.1954-1962.
CrossRef
PubMed
- Ristich V., Liang S., Zhang W. Tolerization of dendritic cells byHLA-G . Eur. J. Immunol. 2005. 35. P.1133-1142.
CrossRef
PubMed
- Rouas-Freiss N., Marchal R.E., Kirszenbaum M. The alpha1 domainof HLA-G1 and HLA-G2 inhibits cytotoxi city induced by natural killercells: Is HLA-G the public ligand for natural killer cell inhibitoryreceptors? . Proc. Natl. Acad. Sci. USA. 1997. 94. P.5249-5254.
CrossRef
PubMed
- Sato K., Ozaki K., Oh I. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells . Blood. 2007. 109. P.228-234.
CrossRef
PubMed
- Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N., Carosella E.D., Deschaseaux F. Epub 2007 Oct 11. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells . Stem. Cells. 2008. 26. P.212-222.
CrossRef
PubMed
- Si Y.L., Zhao Y.L., Hao H.J., Fu X.B., Han W.D. MSC: Biological characteristics, clinical ap. plications and their outstanding concerns . Ageing Res Rev. 2011. 10. P.93-103.
CrossRef
PubMed
- Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2 . Blood. 2008. 111. P.1327-1333.
CrossRef
PubMed
- Stamler J.S., Singel D.J., Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms . Science. 1992. 258. P 1898-1902.
CrossRef
PubMed
- Togel F., Weiss K., Yang Y., Hu Z., Zhang P., Westenfelder C. Vasculotropic, paracrine a ctions of infused mesenchymal stem cells are important to the recovery from acute kidney injury . Amer. J. Physiol. Renal. Physiol. 2007. 292. P.1626-1635.
CrossRef
PubMed
- Uyttenhove C., Pilotte L., Theate I. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase . Nat. Med. 2003. 9. P. 1269-1274.
CrossRef
PubMed
- Xi-Ping Huang, Ph.D. Zhuo Sun M.D., Yasuo Miyagi M.D., Heather McDonald Kinkaid, MSc Li Zhang M.D., PhD Differentiation of Allogeneic Mesenchymal Stem Cells Induces Immunogenicity and Limits Their LongTerm Benefits for Myocardial Repair . Circulation. 2010. 122. P.2419-2429.
CrossRef
PubMed
- Yasez R., Lamana M.L., Garcta-Castro J., Colmenero I., Ramtrez M., Bueren J.A. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versushost disease . Stem Cells. 2006. 24. P.2582-2591.
CrossRef
PubMed
- Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy . Blood. 2005. 106. P.1755-1761.
CrossRef
PubMed
- Zhang M., Mal N., Kiedrowski M., Chacko M., Askari A.T., Popovic Z.B., Koc O.N., Penn MS. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction . FASEB J. 2007. 21. P.3197-3207.
CrossRef
PubMed
|
|
|
|
|
|
|